Kornimate/medical-research-clean huggingface dataset:
choices: family physicians treat overweight children

Conditions: Obesity; Overweight

Summary: choices is a program to provide children and families with lifetime tools and lifestyle strategies to achieve and maintain a healthy body size. both parents and children get active, learn about the food choices they can make, and about the roles of tv in their lives. led by physicians and young adults, the 12 weekly 90 minute sessions provide hands on experiences that connect into the participants' daily lives. in the study, the families were divided into two groups, beginning their classes 6 months apart. body measurements were taken at baseline and every 4 months to 16 months.

the specific aim of this pilot study was to use the group office visit model to provide an obesity treatment intervention for children 8-11 years of age in gender-specific groups and their parents in a clinic setting. the targeted lifestyle components of the intervention are less tv viewing, less sweetened beverages, smaller food portions, less fast food/better choices away from home and more general physical activity. the psychosocial component was based in resiliency; the choices model focused on a non-judgmental approach to empowerment in relation to personal goals and knowledge of the basics of nutrition and physical activity. our aim was to recruit 35-40 children (approximately equal boys and girls) ages 8-11 and their parents for a 12 weekly sessions group office visit program. participants were randomized into 2 groups; one group starting in march 2006 and the lagged intervention control group starting in september 2006. physical measurements and data collection were at baseline, 4, 8, 12, 16 months from randomization. we evaluated the acceptability and feasibility of the group office visit model and effect size (body mass index (bmi) and weight-for-age z-scores). feasibility and acceptability included ability to recruit within clinics, attendance, completion, follow-up rates, focus groups data and interviews of those who drop out. evaluation of effect size included the patterns of growth over 15 months from baseline in relation to expected growth patterns and intervention exposure.

Eligibility criteria:
inclusion criteria: * children in the 3rd to 5th grades and above the 85th percentile of bmi for age. exclusion criteria: * conditions that would preclude dietary change or physical activity.

Keywords: pediatric obesity resiliency physical activity dietary patterns children
sophrology and congenital heart disease

Conditions: Congenital Heart Disease

Summary: the sophro-care trial aims to measure the impact of sophrology on exercise capacity of adolescents and young adults with congenital heart disease. investigator hypothesized that a series of group sessions of sophrology may improve the exercise capacity, in this population.

adolescents and adults with congenital heart disease (chd) have reduced exercise capacity compared to the general population. our recent randomized trial in a population of children and adolescents with asthma showed that sophrology improve lung function (nct02114398). sophrology, from the greek "study of consciousness in harmony", is an adjuvant therapy, considered in healthcare as a relaxation technique, mainly based on breathing. investigator assume that adolescents and young adults (13-25 y.o.) with chd who participate in a program of sophrology with structured group sessions will improve their exercise capacity as measured by the maximum oxygen uptake (vo2max), in comparison with a control group.

Eligibility criteria:
inclusion criteria: * patient aged 13 to 25 years old * with a congenital heart disease (chd) as defined in the international anatomic and clinical classification (acc) - chd classification. * informed consent from adult patients or parents/legal guardians for minor patients exclusion criteria: * medical contraindication to perform an exercise test. * patient already included in a clinical trial. * cardiac surgery planned during the study * severe intellectual disability that does not allow practice of sophrology exercise or questionnaires to be completed .
assess the safety and effectiveness of once daily pmr compared to twice daily pletaal® in patients with intermittent claudication

Conditions: Intermittent Claudication

Summary: the study is designed to compare the efficacy and safety of once daily pmr treatment with twice daily pletaal® treatment in patients with intermittent claudication caused by peripheral arterial disease and are currently treated with cilostazol of any strength and any dosing frequency.


Eligibility criteria:
main inclusion criteria: * stable use of cilostazol of any strength and any dosing frequency for at least 3 months prior to screening, for the treatment of peripheral arterial disease. * initial claudication distance ≥ 30 meters at the constant workload treadmill test. main exclusion criteria: * presence of limb-threatening chronic limb ischemia, manifested by ischemic rest pain, ulceration or gangrene. * history of lower-extremity surgical or endovascular arterial reconstructions or sympathectomy within 3 months prior to screening. * presence of illness(es) (such as angina pectoris, respiratory disease, orthopaedic disease, or neurological disorders, except the study disease) limiting the exercise capacity. * presence of uncontrolled hypertension (based on physician's judgment) or other unstable cardiovascular disease such as congestive heart failure of any severity and myocardial infarction within 6 months prior to screening. * history of coronary artery bypass graft (cabg) or major cardiovascular surgical procedures within 6 months prior to screening. * history of buerger's disease or deep vein thrombosis within 3 months prior to screening. * presence of haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. * presence or history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular tachycardia with or without adequate treatment, qtc prolongation associated with cardiac disorders, or severe tachyarrhythmia within 6 months prior to screening, which is considered not suitable for this study by investigator. * history of type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus. * use of anticoagulant agent(s) within 6 months prior to screening. * use of two or more than two anti-platelet agents within 3 months prior to screening.

Keywords: peripheral arterial disease ankle brachial index absolute claudication distance initial claudication distance pmr cilostazol
the natural history of atopic disease in thai children and association with atopic march

Conditions: Atopic Dermatitis

Summary: atopic dermatitis(ad) is one of manifestation in atopic march. the prevalence of ad is increased. in 1998, the investigators found the prevalence of ad about 15 % in thailand. ad is diagnosed by clinical as hanifin and rajka criteria. there are 3 group of severity defined by scorad(scoring atopic dermatitis) : mild (\ 50). the natural history of ad was mentioned in 3 groups: complete remission, persistent and intermittent. atopic march is the progression of atopic disease that has atopic dermatitis as the first manifestation then patients will have allergic rhinitis or asthma in the future. the investigators do a retrospective study to understand the natural history of ad as well as it associate with atopic march. that might be a predictive factor of ad and atopic march

retrospective review from out patient record. collect the demographic data, onset of atopic march, sensitization of allergen and treatment that given to patients. for patients who have current follow up at allergy clinic, the current symptom was collect in that visit. for patients who didn't have follow up visit, telephone interview was done. if they have symptom, investigators will ask them to come in for investigation and proper treatment. patient was recruited in this study with parental permission. the data will collect and use statistical analysis.

Eligibility criteria:
inclusion criteria: * diagnosis of ad by physician at birth-15 years old * diagnosed by physician by hanifin and rajka criteria: itching, dry skin, chronic dermatitis : at face, extensor area (infant), flexor area (children and adult), with or with out history of atopy in family * follow at allergy clinic once a year or can ask current symptom via telephone interview. * evaluate severity of the disease by scorad (scoring atopic dermatitis ) exclusion criteria: * onset of atopic dermatitis more than 15 years old. * other disease: skin, cardiovascular, liver disease, endocrine, neurology, ect * not complete data collection in case record form in out patient record. * cannot be reach current symptom of patient.

Keywords: natural history atopic dermatitis atopic march
lactobacillus rhamnosus gg oral treatment efficacy on vernal keratoconjunctivitis treatment

Conditions: Vernal Keratoconjunctivitis

Summary: this interventional study aims to evaluate the efficacy of oral administration of lactobacillus rhamnosus gg in preventing relapses of ocular inflammation in vernal keratoconjunctivitis (vkc) patients.

vernal keratoconjunctivitis (vkc) is a chronic allergic disease, characterised by ocular surface inflammation lasting all year with seasonal relapses. active phases of vkc are characterised by intense ocular symptoms and require treatment with topical steroids to control inflammation and corneal damage. to date, safe and effective therapies in preventing relapses of vkc are not available. recently, the use of oral administration of probiotics for allergic diseases have been proposed. no data are available on the effects of probiotics on ocular allergies. this multicenter, double-masked, randomised, controlled clinical trial will allow to obtain more data on the efficacy of oral treatment with lactobacillus rhamnosus gg in patients affected by vkc. patients with vkc will be treated with lactobacillus rhamnosus gg or placebo in addition to ketotifen fumarate 0.025% eye drops (standard treatment). the number of relapses per year, signs and symptoms of the disease, total symptom score (tsys), total sign score (tss), biochemical and molecular parameters will be evaluated at different time points.

Eligibility criteria:
inclusion criteria: * diagnosis of vkc performed on the basis of personal and family history of systemic allergic diseases, clinical examination (presence of conjunctival tarsal and/or limbal papillae) and presence of eosinophils in the conjunctival scraping. exclusion criteria: * contact lens wearers, * patients affected by other ocular diseases, * patients subjected to ocular surgery in the preceding 6 months, * patients under eye drop or systemic treatments for other diseases, * patients enrolled in experimental trials in the preceding 6 months.

Keywords: vernal keratoconjunctivitis probiotic lactobacillus rhamnosus gg children clinical trial
effect of topical active oxygen therapy on surgical site wound healing and microbial colonization

Conditions: Patients Scheduled for Any Oral Surgical Flap Procedure That Require Suturing Will Be Included in This Study

Summary: to assess the antibacterial efficiency of oxygenated gel therapy on wound healing and microbiological colonization around surgical sutures

all the patients who will agree to participate in the study and who will sign the informed consent forms. computer-generated randomization will be used to randomly divide the surgical sites into two groups. control group: will receive no treatment. study group: will receive active oxygen gel around suture. patients scheduled for any oral surgical flap procedure that require suturing will be included in this study. after flap approximation, the surgical site will be sutured using 5-0 braided sutures. in the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab, three times a day after brushing their teeth. also, patients will be given instructions regarding their post-surgical care.

Eligibility criteria:
inclusion criteria: * adult patients in a healthy systemic condition who required comprehensive dental treatment * both genders with age group \> 18 years old * patients should approve to deliver a signature to a written consent after study nature explanation. exclusion criteria: * patients with severe smoking habits \>10 cig \\ day * pregnant females, decisional impaired individuals and handicapped patients * patients having poor oral hygiene or not wanting to carry out oral hygiene measures * patients on any medication affecting the soft tissue health (e.g., amlodipine, cyclosporine a, hydantoin)

Keywords: active oxygen sutures flap microbiology wound healing
spanish registry of esophagogastric cancer

Conditions: Esophageal Cancer; Gastric Cancer

Summary: this study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the agamenon - seom group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.

patient data will be collected from medical records retrospectively.

Eligibility criteria:
inclusion criteria: * adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbb2 overexpression (and tumors in which this data is unknown). * follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause. exclusion criteria: * a patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.

Keywords: gastric cancer gastroesophageal junction cancer esophageal cancer surgery chemotherapy radiotherapy antitargeted drug inmunotherapy
capnography monitoring in ventilated children

Conditions: Child, Only; Infant, Newborn, Diseases; Critical Illness; ARDS, Human; Heart Defects, Congenital; Lung Diseases, Obstructive; Lung Diseases, Interstitial

Summary: end-tidal co2 measurements in children will be assessed for their accuracy with arterial co2 measurements.

end-tidal and arterial co2 measurements will be performed in invasively and non-invasively ventilated critically ill children. the endtidal co2 values will assessed for their accuracy with respect to different underlying diseases and conditions of the children.

Eligibility criteria:
inclusion criteria: * children on pressure controlled mechanical invasive or non-invasive ventilation on the paediatric intensive care unit of the university children's hospital zurich * newborns with a birthweight of at least 2.0 kg * newborns with an age of at least 1 hour (age \> 60 minutes) * children up to the last day of the 13th year of living * ability of care taker or patient to understand verbal and written instructions and the general consent or informed consent in german or english * obtained written general or informed consent as documented by signature * available arterial line, i.e. a specific catheter inserted in an artery exclusion criteria: * care taker or participant unable for linguistic, mental or other reasons or unwilling to understand verbal or written information and to give written informed consent in german or english * care taker not available * newborns with a birthweight below 2.0 kg * newborns younger than 1 hour (age \<60 minutes) * children with an age of 14 years onwards * missing arterial line * patients dependent on any other kind of respiratory support that is not compatible with the pcco2-sensor or where a high leakage in the respiratory circuit makes pcco2 measurements impossible (nasal mask ventilation, low-flow-/high-flow-ventilation, rebreathing mask, high- frequency-oscillation) * patients where the investigators act on the assumption that mechanical ventilation will be discontinued and/or the arterial line will be removed within 6 hours or where only one pair of values (arterial and endtidal co2) can be compared * patients with a cyanotic shunt lesion with a weight of 15 kg or above

Keywords: capnography end-tidal co2 critically ill children ventilated accuracy
a study to evaluate the efficacy and safety of vb-201 in patients with psoriasis

Conditions: Psoriasis

Summary: this study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by psoriasis area and severity index(pasi), body surface area (bsa), dermatology life quality index (dlqi) and other assessments.


Eligibility criteria:
inclusion criteria: * male or female subjects, ≥18 to ≤75 years of age, who have a diagnosis of chronic plaque psoriasis for at least 6 months prior to screening; * plaque psoriasis covering between 10% to 30 % of body surface area (bsa); * pasi severity moderate to severe, scoring at least 10 but no higher than 20. exclusion criteria: * the subject presents with psoriasis that is predominantly guttate, erythrodermic, inverse, pustular or palmo-plantar or an unstable form of psoriasis; * previously failed (due to lack of efficacy) treatment with at least one systemic biologic agent for psoriasis (e.g. ustekinumab, adalimumab, etanercept, etc); * the subject has not undergone wash-out periods of sufficient duration for the following treatments at baseline: topical psoriasis treatments: 2 weeks; systemic (non-biologic) psoriasis treatments: 4 weeks or 5 half-lives (whichever is longer); biologic psoriasis treatments: 8 weeks or 5 half lives (whichever is longer); phototherapy: 4 weeks; * the subject anticipates getting enough ultra-violet light during the study (e.g. sunbathing; tanning salon, etc.) to cause psoriasis to improve; * history of cancer, with the exception of skin cancer.
a study of people with cd30 positive lymphoma in china

Conditions: Lymphoma

Summary: the main aim is to see how adult participants with newly diagnosed or relapsed/refractory cd30+ lymphoma responded to any previous treatment in china. the study sponsor will not be involved in how participants are treated, the study only consists of collecting demographic and clinical records information from the hospital clinical systems. based on the diagnosis of the disease, participants will be assigned to one of the following groups and their information will be analyzed within that group respectively: * group a: participants diagnosed with classical hodgkin lymphoma (chl). * group b: participants diagnosed with non-hodgkin lymphoma (nhl), including systemic anaplastic large-cell lymphoma \[salcl\], peripheral t-cell lymphoma-not otherwise specified \[ptcl-nos\], angioimmunoblastic t-cell lymphoma \[aitl\], extranodal nk/t-cell lymphoma \[enktcl\], mycosis fungoides \[mf\], primary cutaneous anaplastic large cell lymphoma \[pcalcl\], diffuse large b-cell lymphoma \[dlbcl\], primary mediastinal b-cell lymphoma \[pmbcl\]).

this is an observational, non-interventional, retrospective study in participants with newly diagnosed or relapsed/refractory cd30+ lymphoma to describe the treatment pathways, outcomes, and resource use among adult participants. the study will enroll approximately 2800 participants. the data will be collected from participants' medical records between january 1, 2018 and march 31, 2021 and recorded in the in case report forms (crfs). participants will be assigned to the following two observational cohorts based on pathological diagnosis: * cohort a: participants with chl * cohort b: participants with nhl this multi-center trial will be conducted in china. all participants will be observed for at least 6 months or until death, loss to follow-up, or end of the study, whichever occurs first.

Eligibility criteria:
inclusion criteria: 1. who newly diagnosed with or refractory/relapsed with chl, salcl, cd30+ non-salcl-nhl confirmed by immunochemistry with any cd30 expression (that is, ptcl-nos, aitl, enktcl, mf, pcalcl, dlbcl, pmbcl) between january 1, 2018 and march 31, 2021 and only one cd30+ pathology report will be needed for cd30+ non-salcl-nhl. 2. who have received anti-lymphoma treatment between january 1, 2018 and march 31, 2021. exclusion criteria: 1. whose demographics and clinical features are not available from medical records.

Keywords: drug therapy
pilot testing a new computer-based screening tool to detect cognitive impairment

Conditions: Cognitive Impairment

Summary: a computer-based neuropsychological assessment tool is being developed to help primary care physicians detect neurological and psychiatric disorders. the first version will be tested against current tests to confirm the tool's effectiveness. data will be collected on how well the tool detects disease, how well patients understand the instructions and enjoy performing the tasks, and if particular trials or stimuli are too difficult or too easy for all subjects. adjustments can then be made to the assessment tool, if needed. the initial participants will be age fifty-five to seventy-five with early dementias or mild cognitive impairment to reduce variability.

the investigators are developing a computer-based neuropsychological assessment tool to help primary care physicians detect neurological and psychiatric disorders. to confirm the tool's efficacy, the investigators will first test the prototype against established tests. the investigators propose to collect preliminary data on a limited group of subjects and age-matched controls. collecting data on a limited group of subjects provides early insight into how well the tool detects disease, how well patients understand the instructions and enjoy performing the tasks, and if particular trials or stimuli are too difficult or too easy for all subjects. with this information, the investigators can make adjustments to the tool if needed and collect additional data on revised versions of the tool. the data will be used to establish the validity, reliability and sensitivity of the tool to generate consistent and accurate scores. the investigators will initially focus on a limited age range (age fifty-five to seventy-five) and limited set of diseases (early dementias or mild cognitive impairment) to reduce variability within the patient and control groups and to gain more statistical power with a smaller group of subjects.

Eligibility criteria:
inclusion criteria: * any subject with mild impairment from who has already undergone or will soon undergo a full neuropsychological evaluation. * subjects with clinical dementia rating scale cdr of 0.5-1.0 and mini-mental score 20-26 (or moca equivalent, borderline/mild dementia) will be eligible for this group. * normal controls without exclusion criteria. exclusion criteria: * subjects whose impairment is severe enough to limit their ability to perform the computer-based tasks and/or to provide consent. * subjects with history of learning disabilities or mental illness including major depression, bipolar disorder, anxiety disorders, and addiction are excluded because these problems can affect cognitive performance.

Keywords: neuropsychological assessment cognitive impairment computer-aided diagnostic tool